Verona Pharma (VRNA) Projected to Post Quarterly Earnings on Thursday

Verona Pharma (NASDAQ:VRNA) is expected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $26.49 million for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Verona Pharma Stock Performance

Shares of NASDAQ VRNA opened at $65.60 on Tuesday. The company has a quick ratio of 12.88, a current ratio of 13.03 and a debt-to-equity ratio of 0.93. The firm’s 50-day moving average price is $53.10 and its two-hundred day moving average price is $40.04. Verona Pharma has a 52-week low of $11.39 and a 52-week high of $68.64. The stock has a market capitalization of $5.28 billion, a P/E ratio of -34.17 and a beta of 0.41.

Insiders Place Their Bets

In other news, CEO David Zaccardelli sold 98,888 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $5.01, for a total transaction of $495,428.88. Following the transaction, the chief executive officer now directly owns 15,078,624 shares in the company, valued at $75,543,906.24. The trade was a 0.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Mark W. Hahn sold 98,704 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $5.01, for a total transaction of $494,507.04. Following the transaction, the chief financial officer now owns 14,177,296 shares in the company, valued at approximately $71,028,252.96. This represents a 0.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 710,888 shares of company stock worth $3,559,881. Corporate insiders own 4.80% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target (up previously from $42.00) on shares of Verona Pharma in a report on Tuesday, January 21st. Canaccord Genuity Group lifted their price target on Verona Pharma from $44.00 to $72.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Wells Fargo & Company boosted their target price on Verona Pharma from $64.00 to $74.00 and gave the stock an “overweight” rating in a report on Wednesday, January 8th. Roth Capital raised Verona Pharma to a “strong-buy” rating in a report on Friday, January 10th. Finally, Truist Financial reissued a “buy” rating and set a $57.00 target price (up previously from $44.00) on shares of Verona Pharma in a report on Wednesday, January 8th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $57.14.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.